There is no doctor in space... how is the treatment done if an astronaut falls ill? Find out here...
There is no doctor in space, then how is the treatment done if an astronaut falls ill?
Indian Air Force Group Captain Shubhanshu Shukla is currently in the International Space Station (ISS). He has reached the space station under the Axiom-4 Mission of NASA, ISRO, European Space Agency and private company Axiom Space. Shubhanshu Shukla is the second person to step into space and the first Indian to reach the ISS. There are many astronauts present in the International Space Station at all times and from time to time astronauts are called back to Earth and new people are sent to space. Many people spend months in the space station, while some astronauts have to stay there for a long time.
By June 2025, more than 280 astronauts from more than 20 countries of the world have visited the International Space Station (ISS). These astronauts live in microgravity conditions in Earth's orbit for several weeks and months. The main objective of these missions is scientific experiments and global cooperation. Astronauts are also humans and humans fall ill.
What happens if an astronaut falls ill in space?
There is no hospital or emergency room in space. However, space agencies make full preparations for medical emergencies. Astronauts are given first aid training before going into space and necessary medical devices are available on the ISS. In every mission, an astronaut is nominated as a 'crew medical officer,' who usually has medical training, although he is not a doctor. This medical officer has a medical kit, which contains pain medications, antibiotics, allergy medications, portable ultrasound device, defibrillator and CPR equipment.
Why CPR is not possible?
According to NASA, it is difficult to perform CPR in zero gravity because it becomes difficult to press the chest in space. For this, there is a special device or arrangement to tie the legs so that CPR can be given. If an astronaut faces any serious problem in space, then the astronaut is not alone. Telemedical assistance is provided by doctors through real time video and audio from NASA's Mission Control Center. Based on the biometric data received from the ISS, the doctors give them step-by-step instructions. With the help of this, the astronaut is treated.
What is the provision for emergency services?
If an astronaut's health deteriorates and treatment is not possible on the ISS, there is a provision for emergency evacuation. There is always at least one Soyuz or SpaceX Dragon capsule docked on the ISS, which can bring an astronaut back to Earth in 3-5 hours. Usually this capsule lands in the plains of Kazakhstan. From there, the patient is immediately admitted to the medical center of NASA or the Russian Space Agency. However, this emergency evacuation arrangement is kept as a last resort, because some diseases can worsen after returning to Earth's gravity. In more than 20 years of operation of the ISS, no astronaut has yet had to be brought back due to a medical emergency.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Sunscreen Isn't Seasonal—It's Essential for Year-Round Skin Health
Many people still see sunscreen as a summer-only staple, reserved for beach days or tropical vacations. But the truth is, UV rays are present all year, regardless of season or weather. UVA rays responsible for premature aging and skin cancer penetrate clouds, windows, and even car windshields. Up to 80% of UV radiation can pass through overcast skies, and reflective surfaces like snow, sand, and water can double your exposure. Damage from this invisible assault is cumulative, permanent, and often goes unnoticed until it's too late. Aniruddha Ghosh,Dermatologist, MD - Dermatology , Venereology & Leprosy, Ghosh Clinic, Kolkata Over 80% of our sun exposure is incidental, picked up during everyday tasks like walking to work, driving, or sitting near a window. Skin aging —wrinkles, pigmentation, loss of elasticity is driven more by UV damage than by time. And while melanin offers some natural protection, it doesn't make darker skin immune to UV-related damage or skin cancer. Jyoti Agarkar, Dermatologist, Glamore Clinic, Mumbai Skipping sunscreen in winter or on cloudy days allows invisible damage to accumulate. This can lead to not only cosmetic concerns but also serious health risks. In fact, most skin cancers are directly linked to preventable UV exposure. Kathakali Chatarjee, Dermatologist, MD - MD- Skin & VD, Kolkata Sunscreen isn't just a beauty product; it's a basic health habit—akin to brushing your teeth or wearing a seatbelt. Daily SPF use helps protect your skin's appearance and integrity, supports long-term skin health, and reduces cancer risk. Nidhi Jindal, Dermatologist, MBBS, MD - Dermatology, Oliva Skin & Hair Clinic, Kolkata Ultimately, using sunscreen daily isn't just skincare—it's self-care. It's a small daily step toward protecting your future self. By making it a habit, you help halt the damage that accumulates silently from UV exposure over time. So whether it's sunny, cloudy, or cold, remember: sunscreen is not seasonal. It's essential. Sandip Lathiya, Dermatologist, MD - Dermatology , Venereology & Leprosy, Dr. Lathiya'S Skin Hair & Laser clinic, Bhavnagar, Gujarat The HALT THE DAMAGE, FACE THE WORLD campaign by LUPIN addresses the growing threat of sun damage among the Indian population. With rising UV exposure and rising pollution levels, contributing to Skin Damage by causing issues such as Pigmentation, Breakouts, and Premature aging. The campaign urges early education on the importance of Daily Sun Protection, and Proactive Skincare to Halt the Skin Damage, by promoting awareness and encouraging consistent use of dermatologist-backed solutions, this initiative empowers individuals to take control of their skin health before the damage becomes permanent. It's a vital step toward building a sun-smart generation that faces the world with confidence and care. Disclaimer - The above content is non-editorial, and ET Healthworld hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
India.com
an hour ago
- India.com
From Lucknow To Stars: 5 Lesser-Known Facts About Shubhanshu Shukla – 1st Indian On International Space Station
photoDetails english 2923252 Axiom Space's Axiom Mission 4 (Ax-4) crew successfully reached the International Space Station (ISS) on Thursday in a journey that lasted approximately 28 hours. The SpaceX Dragon spacecraft docked with the International Space Station Harmony module at 6:21 am ET while soaring over the expansive North Atlantic, according to ANI, Axiom stated in a statement. Group Captain Shubhanshu Shukla is part of Axiom Space's mission, marking a historic moment for India's space collaboration with NASA. Updated:Jun 27, 2025, 06:42 PM IST His NDA Secret 1 / 7 According to a report by News18, Shubhanshu Shukla applied secretly to the National Defence Academy (NDA) at the young age of 16. (Photo Credit: @Axiom_Space/ X) Shubhanshu Shukla's School 2 / 7 According to several media reports, astronaut Shubhanshu Shukla did his schooling at City Montessori School. The family of Group Captain Shubhanshu Shukla arrived at his school in Lucknow on June 26 to watch the successful docking of Axiom 4 Mission to the ISS. (Photo Credit: @Axiom_Space/ X) What Did He Take With Him? 3 / 7 Reports have also stated that Group Captain Shubhanshu Shukla is carrying gajar halwa, moong dal halwa, and mango juice with him. (Photo Credit: @Axiom_Space/ X) Shubhanshu Shukla's Wife 4 / 7 According to a Times of India report, Shubhanshu Shukla and his wife, Kamna, met during their school years in Lucknow. Reportedly, she is a dentist by profession. (Photo Credit: @Axiom_Space/ X) Second Indian In Space 5 / 7 After Rakesh Sharma went to space in 1984, astronaut Group Captain Shubhanshu Shukla is the second Indian to travel to space. (Photo Credit: @Axiom_Space/ X) Record As 1st Indian at ISS 6 / 7 Axiom-4 mission Pilot and Indian Air Force (IAF) Group Captain, Shubhanshu Shukla, is the first Indian to enter the International Space Station (ISS). (Photo Credit: @Space_Station/ X) Message From Space 7 / 7 As per ANI, in a message to Indians (in Hindi), Shubhanshu Shukla said, "I have a small message for my countrymen: It is because of your love and blessings that I have safely reached the International Space Station. It may look easy to stand here, but it is not; my head is aching. However, we will get used to it. We will be here for 14 days, conducting scientific experiments and speaking with you. This is a milestone for India. Let's make this journey exciting and let everyone participate with interest." "The Tricolour I bear on my shoulder makes me feel as though the entire country is with me. I believe the next 14 days are going to be truly interesting," he added. (Photo Credit: @Axiom_Space/ X)
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Genomic testing sees sharp uptake in India, now growing beyond metros
With 18 per cent CAGR, India's genomic diagnostics market is expanding into Tier 2 and 3 cities as affordability, cancer screening, and personalised care fuel adoption Anjali Singh Mumbai Demand for genomic testing in India has surged significantly over the past two to three years, fuelled by growing clinical awareness, rapid technological advancements and the rising adoption of personalised medicine. From being a niche service concentrated in major metros, genomic diagnostics are now expanding into Tier 2 and Tier 3 cities, reshaping the landscape of preventive and precision healthcare. The Indian genomic diagnostics market is valued at $550 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 18 per cent, reaching $2,066.31 million by 2030, according to industry estimates. Key drivers include wider physician adoption, declining test prices, improved accessibility and a shift in consumer behaviour towards proactive and personalised healthcare. Diagnostic majors such as Agilus Diagnostics, Metropolis Healthcare, Dr Lal PathLabs, Mahajan Imaging and Labs, and Redcliffe Labs report double-digit growth in the segment. While metros like Mumbai, Bengaluru and Delhi still contribute the lion's share, growing awareness and infrastructure in cities like Lucknow, Bhubaneswar, Pune, Kochi and Surat are driving demand beyond urban hubs. Test affordability has improved substantially. Prices for routine genomic tests—like BRCA1/2 (used to analyse a person's DNA to identify mutations in genes that increase the risk of breast and ovarian cancer) and NIPT (non-invasive prenatal testing, a blood test performed on pregnant women to assess the risk of certain genetic conditions in the foetus)—have come down by 30–40 per cent, now ranging between Rs 5,000 and Rs 20,000, depending on complexity. While advanced oncology panels and exome sequencing can still cost up to Rs 2 lakh, widespread adoption of high-throughput platforms and in-house test development has made even complex testing more accessible. Experts believe that although demand for genomic testing is rising across multiple segments, increasing cancer incidence and a countrywide focus on cancer detection and reproductive health have been key growth drivers. 'The rapid increase in demand for cancer tests, along with paediatric and reproductive health applications like prenatal testing and carrier testing, are major contributing factors driving growth in genetic testing. The country is also witnessing a rise in testing for rare genetic diseases, driven by India's huge genetic diversity,' said Nilaya Varma, group chief executive officer and co-founder, Primus Partners. 'Genomic testing now contributes 5–7 per cent of our total diagnostics revenue, up from under 2 per cent three years ago,' said Anand K, managing director and chief executive officer, Agilus Diagnostics. Redcliffe Labs pegs this number even higher, at 30–40 per cent, with consistent 20 per cent year-on-year growth in test volumes. 'We've seen a dramatic rise in genomic testing demand over the past five years, especially in oncology, rare diseases and reproductive health. What's encouraging is that Tier 2 and 3 cities like Lucknow, Bhubaneswar and Coimbatore are now actively adopting these tests,' said Himani Pandey, lab head – genomics, Redcliffe Labs. Metropolis Healthcare, which entered the genomics space three years ago, has seen over 50 per cent revenue growth in the segment and plans further expansion through investments in bioinformatics and next-generation sequencing (NGS) platforms. 'We've seen over 50 per cent revenue growth in genomics since our entry into the space three years ago. Genomic testing is increasingly being integrated into routine health check-ups, cancer diagnostics, rare disease screening and personalised treatment planning. We are investing heavily in bioinformatics and NGS platforms to scale further,' said Kirti Chadha, chief scientific and innovation officer, Metropolis Healthcare. Similarly, Dr Lal PathLabs, through its genomics division Genevolve, has launched over 500 tests covering oncogenomics, neurogenomics, rare disease panels and reproductive health. 'With Illumina's NovaSeq X platform at our national reference lab and a focused genomics sales team, we're bringing cutting-edge testing to both metros and smaller towns,' said Shankha Banerjee, chief executive officer, Dr Lal PathLabs. While margins on genomic tests can vary—and in many cases remain lower than routine diagnostics due to high input costs and low volumes—players see genomics as a long-term strategic bet. 'It's not just about margins—it's about clinical value and helping doctors make better treatment decisions,' said Shelly Mahajan, lab director at Mahajan Imaging. A common thread across players is the push for in-house development and Indian population–specific panels, often coupled with global partnerships for specialised tests. Most labs are also investing in AI-driven bioinformatics, advanced molecular labs and automation to enhance scalability. Yet, challenges remain. Despite cost reductions, insurance coverage for genomic tests in India is still extremely limited, creating affordability barriers for patients in lower-income segments. Industry leaders stress that broader insurance inclusion could accelerate adoption, particularly for cancer, rare diseases and reproductive health-related tests. Nonetheless, the momentum is clear: Genomic testing is no longer a fringe offering. With its ability to provide deep molecular insights for early diagnosis, targeted therapy and risk prediction, it is fast becoming a core pillar in India's diagnostics growth strategy.
